Health-related quality of life and asthma control in patients receiving or not receiving biologic treatments for severe asthma. Data from SHARP CRC

<bold>Background:</bold> Biologic treatments are increasingly used in severe asthma. <bold>Aim</bold>: To compare clinical characteristics in patients receiving biologic treatments for ≥1 month compared to those not prescribed a biologic <italic>or</italic> receiving a biologic for <1 month. <bold>Method</bold>: Real-word data from adults in the Severe Heterogeneous Asthma Research Collaboration Patient-centred (SHARP) registry included the Severe Asthma Questionnaire (SAQ), SAQ-global, Asthma Control Questionnaire-6 (ACQ) collected via PatientCoach app and clinical data. Patients established (receiving treatment ≥1 month) or not established (not prescribed or on treatment <1 month) on biologics were compared using t-tests. <bold>Results:</bold> Data were available for 221 participants. 103 not established and 118 established (mean 33 months) on biologics. Questionnaire scores were significantly better in patients established on biologics. Exacerbations and daily ICS use were also significantly lower in this group (Table 1). <bold>Conclusion</bold>: These data show that biologic treatments significantly improve asthma HRQoL and control, while reducing exacerbations and reliance on ICS. Table 1. Means (n) and <italic>SDs</italic> for questionnaires and clinical data for patients established or not on biologics. <table-wrap><object-id>erj;64/suppl_68/PA2168/TB1</object-id><object-id>T1</object-id><object-id>TB1</object-id><table><colgroup><col></col><col></col><col></col></colgroup><tbody><tr><td></td><td>Not established</td><td>Established</td></tr><tr><td> SAQ (1-7) </td><td> 4.12 (63) <italic>1.76</italic> </td><td> 5.38* (75) <italic>1.41</italic> </td></tr><tr><td> SAQ-global (0-100) </td><td> 49.32 (63) <italic>23.89</italic> </td><td> 69.76* (75) <italic>19.09</italic> </td></tr><tr><td> ACQ (6-0) </td><td> 2.50 (81) <italic>1.39</italic> </td><td> 1.41* (96) <italic>1.18</italic> </td></tr><tr><td>BMI</td><td> 30.75 (103) <italic>7.81</italic> </td><td> 32.53 (117) <italic>33.03</italic> </td></tr><tr><td>FEV1</td><td> 2.50 (89) <italic>0.76</italic> </td><td> 2.67 (108) <italic>0.95</italic> </td></tr><tr><td>FEV1%pred</td><td> 83.43 (89) <italic>20.38</italic> </td><td> 83.34 (110) <italic>21.53</italic> </td></tr><tr><td>Exacerbations</td><td> 2.59 (103) <italic>2.47</italic> </td><td> 1.67* (118) <italic>2.26</italic> </td></tr><tr><td>Hospital admissions</td><td> 0.35 (103) <italic>0.74</italic> </td><td> 0.26 (116) <italic>0.74</italic> </td></tr><tr><td>Daily ICS (BDP equivalent)</td><td> 878.05 (97) <italic>1015.59</italic> </td><td> 483.77* (110) <italic>773.29</italic> </td></tr></tbody></table></table-wrap> *p<0.01